Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery
- PMID: 15647188
- PMCID: PMC1774826
- DOI: 10.1136/gut.2004.045294
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery
Erratum in
- Gut. 2005 May;54(5):734
Abstract
Background/aim: Immunosuppressants are now used much earlier in the course of Crohn's disease; however their effect on the natural history of the disease, especially on the need for surgery, is not known. The aim of this study was to assess the evolution of the need for surgery in Crohn's disease during the last 25 years.
Patients and methods: The medical charts of 2573 patients were reviewed retrospectively. The use of immunosuppressants (azathioprine or methotrexate), the need for intestinal resection, and the occurrence of intestinal complications were assessed using Kaplan-Meier analysis in five consecutive cohorts of patients defined by the date of diagnosis of Crohn's disease (1978-82; 1983-87; 1988-92; 1993-97; 1998-2002).
Results: In 565 patients seen in the authors' unit within the first three months after diagnosis, characteristics of Crohn's disease at diagnosis did not differ from one cohort to another. The five year cumulative probability to receive immunosuppressants increased from 0 in the 1978-82 cohort to 0.13, 0.25, 0.25, and 0.56 in the 1983-87, 1988-92, 1993-97, and 1998-2002 cohorts, respectively (p<0.001). Concomitantly, the cumulative risk of intestinal resection remained unchanged (from 0.35 to 0.34 at five years; p=0.81). The cumulative risk of developing a stricturing or a penetrating intestinal complication remained also unchanged. Similar results were obtained in the 2008 patients seen during the same period who were referred to us more than three months after diagnosis.
Conclusion: Although immunosuppressants have been used more frequently over the last 25 years, there was no significant decrease of the need for surgery, or of intestinal complications of Crohn's disease.
Figures


Similar articles
-
Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.Gut. 2010 Sep;59(9):1200-6. doi: 10.1136/gut.2009.202101. Epub 2010 Jul 21. Gut. 2010. PMID: 20650924
-
Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen.Dig Liver Dis. 2009 Apr;41(4):269-76. doi: 10.1016/j.dld.2008.09.010. Epub 2008 Oct 26. Dig Liver Dis. 2009. PMID: 18955023
-
Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.Am J Gastroenterol. 2009 Nov;104(11):2754-9. doi: 10.1038/ajg.2009.387. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584832
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
Clinical factors predictive of Crohn's disease complications and surgery.Eur J Gastroenterol Hepatol. 2013 Feb;25(2):129-34. doi: 10.1097/MEG.0b013e32835a7eed. Eur J Gastroenterol Hepatol. 2013. PMID: 23104203 Review.
Cited by
-
Impact of medical therapies on inflammatory bowel disease complication rate.World J Gastroenterol. 2012 Aug 7;18(29):3823-7. doi: 10.3748/wjg.v18.i29.3823. World J Gastroenterol. 2012. PMID: 22876033 Free PMC article. Review.
-
Prophylaxis of Crohn's disease recurrence: A surgeon's perspective.Ann Gastroenterol Surg. 2020 Jun 24;4(5):514-520. doi: 10.1002/ags3.12368. eCollection 2020 Sep. Ann Gastroenterol Surg. 2020. PMID: 33005846 Free PMC article. Review.
-
Is early limited surgery associated with a more benign disease course in Crohn's disease?World J Gastroenterol. 2013 Nov 21;19(43):7701-10. doi: 10.3748/wjg.v19.i43.7701. World J Gastroenterol. 2013. PMID: 24282358 Free PMC article.
-
Risk factors and implications of anastomotic complications after surgery for Crohn's disease.World J Gastrointest Surg. 2015 Oct 27;7(10):237-42. doi: 10.4240/wjgs.v7.i10.237. World J Gastrointest Surg. 2015. PMID: 26523211 Free PMC article. Review.
-
Medical Therapy of Fibrostenotic Crohn's Disease.Viszeralmedizin. 2015 Aug;31(4):259-64. doi: 10.1159/000435868. Epub 2015 Jul 28. Viszeralmedizin. 2015. PMID: 26557834 Free PMC article. Review.
References
-
- Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med 2001;52:299–318. - PubMed
-
- Feagan BG. Standard immunosuppression in IBD: current practice. Acta Gastroenterol Belg 2001;64:182–8. - PubMed
-
- Korelitz BI, Present DH. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital. Mt Sinai J Med 1996;63:191–201. - PubMed
-
- Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132–42. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical